Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
O75175
UPID:
CNOT3_HUMAN
Alternative names:
CCR4-associated factor 3; Leukocyte receptor cluster member 2
Alternative UPACC:
O75175; Q9NZN7; Q9UF76
Background:
CCR4-NOT transcription complex subunit 3, also known as CCR4-associated factor 3, plays a pivotal role in mRNA deadenylation, influencing various cellular processes such as mRNA degradation, miRNA-mediated repression, and transcription regulation. Its involvement extends to metabolic regulation, mitotic progression, and maintaining embryonic stem cell identity.
Therapeutic significance:
Linked to Intellectual developmental disorder with speech delay, autism, and dysmorphic facies, understanding CCR4-NOT transcription complex subunit 3's role could unveil novel therapeutic strategies.